Bristol Myers Squibb (BMY) on Thursday announced an expansion of its direct-to-patient program, allowing eligible U.S. patients to access Sotyktu at significantly reduced prices.
Starting January 2026, BMS' Sotyktu, indicated for the treatment of moderate-to-severe plaque psoriasis, will be available through the new BMS Patient Connect platform at over 80% off the current list price.
This initiative follows the Bristol Myers Squibb-Pfizer Alliance program, launched earlier this month, which offers the anticoagulant drug Eliquis at a discount of more than 40%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.